Dynamics of Anti-SARS-CoV-2 IgA and IgG Responses and Their Protective Effect against Fatal Disease after Booster COVID-19 Vaccination
During the post-coronavirus disease (COVID-19) era, a primary question is whether booster vaccination is effective against severe COVID-19 and should be recommended, particularly to individuals at high risk for severe disease (i.e., the elderly or those with additional severe comorbidities). From December 2020 to February 2023, a cohort study was conducted to estimate IgG and IgA immunogenicity and the dynamics of booster mono- and bivalent COVID-19 mRNA vaccines in 260 individuals (male/female: 114/146, median age: 68 years, interquartile range (IQR) = 31) who initially received either mRNA (218) or adenovirus-vector-based vaccines (42). Participants were followed until the 90th day after the third booster dose. Our cohort study indicated a beneficial effect of booster vaccination on the magnitude of IgG and IgA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies. We found that second and third booster doses were more protective than one against fatal disease (p = 0.031, OR 0.08). In conclusion, booster COVID-19 vaccination should be strongly recommended, especially to individuals at high risk for severe/fatal disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Vaccines - 12(2023), 1 vom: 21. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Speletas, Matthaios [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-SARS-CoV-2 IgA responses |
|---|
| Anmerkungen: |
Date Revised 29.01.2024 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/vaccines12010012 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367670801 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367670801 | ||
| 003 | DE-627 | ||
| 005 | 20240129232213.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240126s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/vaccines12010012 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1274.xml |
| 035 | |a (DE-627)NLM367670801 | ||
| 035 | |a (NLM)38276671 | ||
| 035 | |a (PII)12 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Speletas, Matthaios |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dynamics of Anti-SARS-CoV-2 IgA and IgG Responses and Their Protective Effect against Fatal Disease after Booster COVID-19 Vaccination |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 29.01.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a During the post-coronavirus disease (COVID-19) era, a primary question is whether booster vaccination is effective against severe COVID-19 and should be recommended, particularly to individuals at high risk for severe disease (i.e., the elderly or those with additional severe comorbidities). From December 2020 to February 2023, a cohort study was conducted to estimate IgG and IgA immunogenicity and the dynamics of booster mono- and bivalent COVID-19 mRNA vaccines in 260 individuals (male/female: 114/146, median age: 68 years, interquartile range (IQR) = 31) who initially received either mRNA (218) or adenovirus-vector-based vaccines (42). Participants were followed until the 90th day after the third booster dose. Our cohort study indicated a beneficial effect of booster vaccination on the magnitude of IgG and IgA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies. We found that second and third booster doses were more protective than one against fatal disease (p = 0.031, OR 0.08). In conclusion, booster COVID-19 vaccination should be strongly recommended, especially to individuals at high risk for severe/fatal disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 mRNA vaccination | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a anti-SARS-CoV-2 IgA responses | |
| 650 | 4 | |a anti-SARS-CoV-2 IgG responses | |
| 650 | 4 | |a booster vaccination | |
| 700 | 1 | |a Voulgaridi, Ioanna |e verfasserin |4 aut | |
| 700 | 1 | |a Bogogiannidou, Zacharoula |e verfasserin |4 aut | |
| 700 | 1 | |a Sarrou, Styliani |e verfasserin |4 aut | |
| 700 | 1 | |a Kyritsi, Maria A |e verfasserin |4 aut | |
| 700 | 1 | |a Theodoridou, Aikaterini |e verfasserin |4 aut | |
| 700 | 1 | |a Dadouli, Katerina |e verfasserin |4 aut | |
| 700 | 1 | |a Matziri, Alexia |e verfasserin |4 aut | |
| 700 | 1 | |a Vontas, Alexandros |e verfasserin |4 aut | |
| 700 | 1 | |a Pappa, Dimitra |e verfasserin |4 aut | |
| 700 | 1 | |a Konstantinou, Adamos-Konstantinos |e verfasserin |4 aut | |
| 700 | 1 | |a Tsigalou, Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Kalala, Fani |e verfasserin |4 aut | |
| 700 | 1 | |a Mouchtouri, Varvara A |e verfasserin |4 aut | |
| 700 | 1 | |a Hadjichristodoulou, Christos |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccines |d 2012 |g 12(2023), 1 vom: 21. Dez. |w (DE-627)NLM239212347 |x 2076-393X |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:1 |g day:21 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/vaccines12010012 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 1 |b 21 |c 12 | ||